drugset

drugset / Trial / NCT07538973

A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function

NCT07538973 ↗

Phase 1 Not yet recruiting 24 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects with Impaired Liver Function versus Normal Liver Function

Timeline

Start: 2026-04
Primary completion: 2027-03
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anecatibin	Unknown	300 mg	—

Indications